广发基金罗国庆旗下广发中证创新药产业ETF一季报最新持仓，重仓药明康德

证券之星04-22

证券之星消息，4月22日广发基金旗下罗国庆管理的广发中证创新药产业交易型开放式指数基金公布一季报，近1年净值增长率15.91%。与上一季度相比，该基金前十大重仓股新增信立泰；并对药明康德增仓222.76万股，为该基金第一大重仓股；艾力斯等退出前十大重仓股；详细数据如下：

以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。

相关 ETF

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2629506945?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-04-22 07:14","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2629506945","market":"fut","top_or_hot":-1,"title":"广发基金罗国庆旗下广发中证创新药产业ETF一季报最新持仓，重仓药明康德","media":"证券之星","content":"<html><body><p>证券之星消息，4月22日<a href=\"https://laohu8.com/S/01776\">广发</a>基金旗下罗国庆管理的广发中证创新药产业交易型开放式指数基金公布一季报，近1年净值增长率15.91%。与上一季度相比，该基金前十大重仓股新增<a href=\"https://laohu8.com/S/002294\">信立泰</a>；并对<a href=\"https://laohu8.com/S/603259\">药明康德</a>增仓222.76万股，为该基金第一大重仓股；<a href=\"https://laohu8.com/S/688578\">艾力斯</a>等退出前十大重仓股；详细数据如下：</p><p><img src=\"https://static.stockstar.com/cmsrobo/fund_holds_515120_1776813263.jpg\"/></p><p>以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。</p><h2>相关 ETF</h2><p><img src=\"https://static.stockstar.com/etf/51608020260421.png\"/></p></body></html>","source":"stockstar","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>广发基金罗国庆旗下广发中证创新药产业ETF一季报最新持仓，重仓药明康德</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n广发基金罗国庆旗下广发中证创新药产业ETF一季报最新持仓，重仓药明康德\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-04-22 07:14 北京时间&nbsp;&nbsp;&nbsp;<a href=https://stock.stockstar.com/RB2026042200013520.shtml><strong>证券之星</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>证券之星消息，4月22日广发基金旗下罗国庆管理的广发中证创新药产业交易型开放式指数基金公布一季报，近1年净值增长率15.91%。与上一季度相比，该基金前十大重仓股新增信立泰；并对药明康德增仓222.76万股，为该基金第一大重仓股；艾力斯等退出前十大重仓股；详细数据如下：以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。相关 ...</p>\n\n<a href=\"https://stock.stockstar.com/RB2026042200013520.shtml\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU1969619763.USD","symbol_name":"EASTSPRING INV CHINA A SHARES GROWTH \"A\" (USD) ACC","start_time":0,"source_url":"https://stock.stockstar.com/RB2026042200013520.shtml","article_id":"2629506945","we_media_id":"1082532455","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2629506945","pubTimestamp":1776813269,"columns":[],"sourceInfo":{"source_id":"stockstar","name":"证券之星"},"weMediaInfo":{"media_name":"证券之星","introduction":"证券之星始创于1996年，是国内领先的金融信息及综合服务平台。关注证券之星，即时获取有价值的财经资讯。","home_visible":1,"id":"1082532455","head_image":"https://community-static.tradeup.com/news/2e305640fc27210243042d09d3a7fa3f"},"summary":"证券之星消息，4月22日广发基金旗下罗国庆管理的广发中证创新药产业交易型开放式指数基金公布一季报，近1年净值增长率15.91%。与上一季度相比，该基金前十大重仓股新增信立泰；并对药明康德增仓222.76万股，为该基金第一大重仓股；艾力斯等退出前十大重仓股；详细数据如下：以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。相关 ETF","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"zh","relate_stocks":{"159992":"创新药","603259":"药明康德","LU1969619763.USD":"EASTSPRING INV CHINA A SHARES GROWTH \"A\" (USD) ACC","LU1979443071.USD":"AB CHINA A SHARES EQUITY PORTFOLIO \"AD\" (USDHDG) INC","LU2495084118.USD":"ALLIANZ CHINA A-SHARES \"ATH\" (USDHDG) ACC","LU0348766576.USD":"ALLIANZ LITTLE DRAGONS \"A\" (USD) INC","LU1046422090.SGD":"Fidelity Pacific A-SGD","LU1997244956.HKD":"ALLIANZ CHINA A-SHARES \"AT\" (HKD) ACC A","BK1161":"生物科技","LU0348767384.USD":"ALLIANZLITTLE DRAGONS \"A\" (USD) ACC","06978":"永泰生物-B","BK1574":"生物医药B类股","LU2242644610.SGD":"Fidelity China Innovation A-ACC-SGD","BK0216":"研究试验","BK1583":"高瓴概念","LU1997245177.USD":"安联神洲A股基金","LU2328871848.SGD":"Eastspring Investments - China A Shares Growth AS SGD","LU1808992512.USD":"AB ALL CHINA EQUITY PORTFOLIO \"A\" (USD) ACC","LU0456842615.SGD":"JPMorgan Funds - Emerging Markets Equity A (acc) SGD","LU2488822045.USD":"ALLIANZ CHINA HEALTHY LIVING \"AT\" (USD) ACC","LU2045819591.USD":"Natixis WCM Global Emerging Markets Equity R/A USD","LU0052750758.USD":"富兰克林中国基金A Acc","LU0320764599.SGD":"FTIF - Templeton China A Acc SGD","LU0708995583.HKD":"TEMPLETON CHINA \"A\" (HKD) ACC","BK1141":"生命科学工具和服务","LU1997245094.SGD":"安联神州A股基金AT Acc SGD","BK1576":"医药外包概念","02359":"药明康德","LU2125910500.SGD":"Natixis WCM Global Emerging Markets Equity H-R/A SGD","LU1934453819.USD":"AB CHINA A SHARES EQUITY PORTFOLIO \"A\" (USD) ACC"},"translate_title":"GF CSI Innovative Drug Industry ETF, a subsidiary of GF Fund Luo Guoqing, reported the latest position in the first quarter, heavily positioned WuXi AppTec","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"159992":1.5,"603259":1.5,"06978":1.5,"02359":1.5},"content_text":"证券之星消息，4月22日广发基金旗下罗国庆管理的广发中证创新药产业交易型开放式指数基金公布一季报，近1年净值增长率15.91%。与上一季度相比，该基金前十大重仓股新增信立泰；并对药明康德增仓222.76万股，为该基金第一大重仓股；艾力斯等退出前十大重仓股；详细数据如下：以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。相关 ETF","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"shareholding","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2629506945","isCrawlerRequest":true}